Traumatic Brain Injury – Neurosurgical pathologies
Clinical Outcomes of MLC601 (NeuroAiD™ ) in Traumatic Brain Injury: A Pilot Study.
Publication : Fauzi AA, Prihastomo KT, Ranuh IGMAR et al. Brain Sci 2020;10;60:1-9. DOI: 10.3390/brainsci10020060
Participation Size : 32
Traumatic Brain Injury – Neurosurgical pathologies
MLC901 (NeuroAiD II™) for cognition after traumatic brain injury: a pilot randomized clinical trial.
Publication : A. Theadom et al. Eur J Neurol. 2018 Apr 3. DOI: 10.1111/ene.13653
Participation Size : 78
Ischemic Stroke
NurAiD-II in stroke recovery: scientific reasoning and real-world evidence.
Publication : De Le Cruz Cosme C. International Journal of Clinical Neurosciences and Mental Health 2017.
Cognitive Disorders and Dementia
MLC601 in vascular dementia: an efficacy and safety pilot study.
Publication : Pakdaman H, et al. Neuropsychiatric Disease and Treatment 2017. DOI: 10.2147/NDT.S145047
Participation Size : 81
Efficacy and Safety of MLC601 in the Treatment of Mild Cognitive Impairment: A Pilot, Randomized, Double-Blind, Placebo-Controlled Study.
Publication : Pakdaman H, et al. Dementia and Geriatric Cognitive Disorders 2017. DOI: 10.1159/000458521
Participation Size : 72
Ischemic Stroke
CHInese Medicine NeuroAiD Efficacy on Stroke Recovery – Extension Study (CHIMES-E): A Multicenter Study of Long-Term Efficacy.
Publication : Venketasubramanian N, et al. Cerebrovascular Diseases 2015. DOI: 10.1159/000382082
Participation Size : 880
Sponsor : CHIMES Society
Cognitive Disorders and Dementia
Effectiveness and Safety of MLC601 in the Treatment of Mild to Moderate Alzheimer’s Disease: A Multicenter, Randomized Controlled Trial.
Publication : Pakdaman, H et al. Dementia and Geriatric Cognitive Disorders 2015. DOI: 10.1159/000375295
Participation Size : 264
Ischemic Stroke
A Randomized Trial to Assess the Long-Term Safety of NeuroAiD among Caucasian Patients with Acute Ischemic Stroke.
Publication : Shahripour RB, et al. Chin J Integr Med 2014. DOI: 10.1007/s11655-014-1687-8
Participation Size : 150
Ischemic Stroke
Chinese Medicine Neuroaid Efficacy on Stroke Recovery: A Double-Blind, Placebo-Controlled, Randomized Study.
Publication : Chen C, et al. Stroke 2013. DOI: 10.1161/STROKEAHA.113.002055
Participation Size : 1099
Sponsor : CHIMES Society
Cognitive Disorders and Dementia
Efficacy and Tolerability of MLC601 in Patients with Mild to Moderate Alzheimer Disease Who Were Unable to Tolerate or Failed to Benefit from Treatment with Rivastigmine.
Publication : Harandi AA, et al. Brit Med Med Res 2013.
Participation Size : 124
Sponsor : Shahid Beheshti University of Medical Sciences
Ischemic Stroke
The Use of NeuroAiD (MLC601) in Post ischemic Stroke Patients.
Publication : Navarro JC, et al. Rehabil Res Pract 2012. DOI: 10.1155/2012/506387
Participation Size : 30
Safety and efficacy of MLC601 in Iranian patients after stroke: a double-blind, placebo-controlled clinical trial.
Publication : Harandi AA, et al. Stroke Res Treat 2011. DOI: 10.4061/2011/721613
Participation Size : 150
Sponsor : Shahid Beheshti University
Ischemic Stroke
The effect of NeuroAiD (MLC601) on cerebral blood flow velocity in subjects’ post brain infarct in the middle cerebral artery territory.
Publication : Shahripour RB, et al. Eur Intern Med 2011. DOI: 10.1016/j.ejim.2011.01.002
Participation Size : 80
NeuroAiD (MLC601) versus piracetam in the recovery of post-infarct homonymous hemianopsia.
Publication : Ghandehari K, et al. Neural Regen Res 2011. DOI: 10.3969/j.issn.1673-5374.2011.06.003
Participation Size : 40
Sponsor : Moleac Pte. Ltd.
Traumatic Brain Injury – Neurosurgical pathologies
Case Report on the Use of MLC601 (NeuroAiD) in Neurosurgical Pathologies.
Publication : Yeo TT, et al. Poster WSC Seoul 2010.
Participation Size : 3
Ischemic Stroke
A Double-Blind, Placebo-Controlled, Randomized Phase II Pilot Study to Investigate the Potential Efficacy of the Traditional Chinese Medicine NeuroAiD (MLC601) in Enhancing Recovery after Stroke (TIERS).
Publication : Kong KH, et al. Cerebrovasc Dis 2009.DOI: 10.1159/000247001
Participation Size : 40
Sponsor : Moleac Pte Ltd.
NeuroAiD (Danqi Piantang Jiaonang), a Traditional Chinese Medicine, in Poststroke Recovery.
Publication : Chen C, et al. Stroke 2009. DOI: 10.1161/STROKEAHA.108.531616
Participation Size : 605
Sponsor : Tianjin University of Traditional Chinese Medicine
Ischemic Stroke
NeuroAiD Danqi Piantang Jiaonang Does Not Modify Hemostasis, Hematology, and Biochemistry in Normal Subjects and Stroke Patients.
Publication : Gan R, et al. Cerebrovasc Dis 2008. DOI: 10.1159/000126919
Participation Size : 64
NeuroAiD in Stroke Recovery.
Publication : Siow C, Eur Neurol 2008. DOI: 10.1159/000155220
Participation Size : 10
Spinal Cord Injury
Assessing Tolerability and Use of Combined Rehabilitation and NeuroAiD (SATURN Study): Protocol of An Exploratory Study In Assessing the Safety and Efficacy of NeuroAiD Amongst People Who Sustain Severe Spinal Cord Injury.
Publication : Kumar JC et al. JMIR Res Protoc 2016. DOI: 10.2196/resprot.6275
Participation Size : 26
Sponsor : Moleac Pte. Ltd.
The NeuroAiD Safe Treatment (NeST) Registry: a protocol.
Publication : Venketasubramanian N, et al. BJM Open 2015. DOI:10.1136/bmjopen-2015-009866
Participation Size : 460
Sponsor : CHIMES Society
The NeuroAiD II (MLC901) in Vascular Cognitive Impairment Study (NEURITES).
Publication : Chen C, et al. Cerebrovasc Dis 2013.DOI: 10.1159/000346234
Participation Size : 103
Sponsor : National University Hospital, Singapore
The Alzheimer’s disease THErapy with NEuroaid (ATHENE) study protocol: Assessing the safety and efficacy of Neuroaid II (MLC901) in patients with mild-to-moderate Alzheimer’s disease stable on cholinesterase inhibitors or memantine-A randomized, double-blind, placebo-controlled trial.
Publication : Chen CLH¹, Sharma PR², Tan BY³, Low C⁴, Venketasubramanian N⁵. Alzheimers Dement (N Y). 2019 Jan 23;5:38-45. doi: 10.1016/j.trci.2018.12.001
Participation Size : 125
